Page last updated: 2024-09-04
pralnacasan and spironolactone
pralnacasan has been researched along with spironolactone in 2 studies
Compound Research Comparison
Studies (pralnacasan) | Trials (pralnacasan) | Recent Studies (post-2010) (pralnacasan) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
---|---|---|---|---|---|
19 | 0 | 7 | 7,222 | 960 | 1,923 |
Protein Interaction Comparison
Protein | Taxonomy | pralnacasan (IC50) | spironolactone (IC50) |
---|---|---|---|
Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
Estrogen receptor | Homo sapiens (human) | 5.702 | |
Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
Progesterone receptor | Homo sapiens (human) | 1.675 | |
Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
Androgen receptor | Homo sapiens (human) | 0.3585 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Reviews
1 review(s) available for pralnacasan and spironolactone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
1 other study(ies) available for pralnacasan and spironolactone
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |